HIMS & HERS HEALTH, INC. vs GeneDx Holdings Corp., two Medical Services stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Negative 56.2 is the number to reckon with: GeneDx's operating margin, spending its way through genomic-testing scale-up, against Hims & Hers' negative 12.9%, a consumer-health brand nearly at break-even (net margin negative 0.6%). The gross margins match at 65-67%, which is the interesting part: both convert product into contribution at software-adjacent rates, and diverge entirely on what they spend below the line. Hims is four times the size, $8B against $2B, with no debt; GeneDx carries 0.39 turns and a 3.1 current ratio runway. Neither prints a multiple. Two loss-makers with identical raw material and opposite proximity to profit; the market sizes them accordingly.
Comparison updated 2026-07-10.
| Metric | HIMS | WGS |
|---|---|---|
| Price | $33.87 | $69.86 |
| Market cap | $7.7B | $2.0B |
| Sector | Medical Services | Medical Services |
| Stage | Growth | Growth |
| P/B | 17.34 | 8.06 |
| P/S | 3.26 | 4.63 |
| EV/EBITDA | 118.1 | — |
| Revenue growth | +38.5% | +35.3% |
| Gross margin | 65.3% | 66.7% |
| Operating margin | -12.9% | -56.2% |
| Net margin | -0.6% | -17.6% |
| Return on equity | -3.0% | -30.6% |
| Return on assets | -0.6% | -15.4% |
| Return on invested capital | 7.4% | -14.7% |
| FCF yield | 0.8% | -1.4% |
| Debt / equity | 0.00 | 0.39 |
| Current ratio | 1.69 | 3.09 |
| Altman Z (solvency) | 3.58 | 1.84 |
| Piotroski F (quality) | 4 / 9 | 1 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.